熱點掃描 | 醫藥股走高，山東新華製藥漲近10%
uSMART盈立智投8月8日消息，截止發稿，港股三大指數漲跌不一，恆生指數跌0.66%，報20069.85點，成交額268.97億；國企指數跌0.86%，報6842.72點，成交額72.51億；紅籌指數漲0.14%，報3609.44點，成交額7.97億。
醫藥股走高，山東新華製藥漲近10%，再鼎醫藥漲近8%，基石藥業漲近5%，信達生物、開拓藥業漲近4%。
熱門股
和黃醫藥漲7.46%，報23.05港元，總市值199.28億港元，該公司發佈公告，呋喹替尼用於探索性治療晚期難治性的轉移性結直腸癌的FRESCO-2關鍵性全球III期研究的已達到總生存期這一主要終點，FRESCO-2研究是一項在美國、歐洲、日本及澳洲開展的全球多中心臨牀試驗，旨在探索呋喹替尼加最佳支持治療對比安慰劑加最佳支持治療用於治療標準化療及相關生物製劑治療後疾病進展或對TAS-102和/或瑞戈非尼不耐受的轉移性結直腸癌患者，除OS外，關鍵次要終點無進展生存期亦觀察到具有統計學意義的顯着改善，呋喹替尼的安全性與先前臨牀試驗中觀察到的一致；
金陽新能源跌5.55%，報12.6港元，總市值215.71億港元，金陽新能源5日發盈警，預計6月止六個月銷售額約1.34億人民幣，較2021年同期減少17.1%，毛利率預計由27.4%降至約1.1%，期內淨虧損將較去年同期的384萬人民幣增加，歸因授出購股的攤銷費用約7,780萬人民幣；
高偉電子再度拉昇漲6.35%，自6月底以來股價漲幅翻倍，現報16.08港元續刷歷史新高價，總市值134億港元，有消息稱iPhone 14上市後的初期銷量將高於一年前的iPhone 13，蘋果分析師郭明錤曾表示，高偉電子將成爲iPhone 14系列前置相機升級的贏家之一，其受益於CCM和VCM的垂直整合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
